Decoy Therapeutics reports preclinical data backing once-weekly intranasal dosing for DCOY-CoV program
DCOY•Decoy Therapeutics disclosed preclinical pharmacokinetic results supporting once-weekly intranasal dosing for its DCOY-CoV program. The findings indicate a single dose could sustain protective drug exposure across the upper airways and lungs for about a week.
1. Preclinical dosing findings
Decoy Therapeutics said its preclinical data support once-weekly intranasal dosing for its lead DCOY-CoV program. The findings indicate a single dose could sustain protective drug exposure across the upper airways and lungs for about a week. The data were scheduled for presentation on September 29 at the Boulder Peptide Symposium’s Peptide Showcase.
2. Program plans
The program targets prevention or treatment of endemic human coronaviruses in high-risk patients, where no non-COVID options are approved. DCOY-CoV is expected to enter clinical trials in 2027.
